114 related articles for article (PubMed ID: 21183939)
1. HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.
Storti P; Donofrio G; Colla S; Airoldi I; Bolzoni M; Agnelli L; Abeltino M; Todoerti K; Lazzaretti M; Mancini C; Ribatti D; Bonomini S; Franceschi V; Pistoia V; Lisignoli G; Pedrazzini A; Cavicchi O; Neri A; Rizzoli V; Giuliani N
Leukemia; 2011 Mar; 25(3):527-37. PubMed ID: 21183939
[TBL] [Abstract][Full Text] [Related]
2. Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma.
Guo D; Li C; Teng Q; Sun Z; Li Y; Zhang C
Neoplasma; 2013; 60(1):33-40. PubMed ID: 23067214
[TBL] [Abstract][Full Text] [Related]
3. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
4. HOXB7: a key factor for tumor-associated angiogenic switch.
Carè A; Felicetti F; Meccia E; Bottero L; Parenza M; Stoppacciaro A; Peschle C; Colombo MP
Cancer Res; 2001 Sep; 61(17):6532-9. PubMed ID: 11522651
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations.
Agnelli L; Storti P; Todoerti K; Sammarelli G; Dalla Palma B; Bolzoni M; Rocci A; Piazza F; Semenzato G; Palumbo A; Neri A; Giuliani N
Am J Hematol; 2011 Dec; 86(12):E64-6. PubMed ID: 21953534
[TBL] [Abstract][Full Text] [Related]
6. Identification of brain-derived neurotrophic factor as a novel angiogenic protein in multiple myeloma.
Hu Y; Wang YD; Guo T; Wei WN; Sun CY; Zhang L; Huang J
Cancer Genet Cytogenet; 2007 Oct; 178(1):1-10. PubMed ID: 17889702
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in multiple myeloma.
Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma.
De Luisi A; Binetti L; Ria R; Ruggieri S; Berardi S; Catacchio I; Racanelli V; Pavone V; Rossini B; Vacca A; Ribatti D
Angiogenesis; 2013 Oct; 16(4):963-73. PubMed ID: 23881169
[TBL] [Abstract][Full Text] [Related]
9. Fucoidan inhibits angiogenesis induced by multiple myeloma cells.
Liu F; Luo G; Xiao Q; Chen L; Luo X; Lv J; Chen L
Oncol Rep; 2016 Oct; 36(4):1963-72. PubMed ID: 27498597
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
11. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition.
Wu X; Chen H; Parker B; Rubin E; Zhu T; Lee JS; Argani P; Sukumar S
Cancer Res; 2006 Oct; 66(19):9527-34. PubMed ID: 17018609
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.
Asosingh K; De Raeve H; Menu E; Van Riet I; Van Marck E; Van Camp B; Vanderkerken K
Blood; 2004 Apr; 103(8):3131-7. PubMed ID: 15070695
[TBL] [Abstract][Full Text] [Related]
13. JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Fan F; Malvestiti S; Vallet S; Lind J; Garcia-Manteiga JM; Morelli E; Jiang Q; Seckinger A; Hose D; Goldschmidt H; Stadlbauer A; Sun C; Mei H; Pecherstorfer M; Bakiri L; Wagner EF; Tonon G; Sattler M; Hu Y; Tassone P; Jaeger D; Podar K
Leukemia; 2021 Dec; 35(12):3509-3525. PubMed ID: 34007044
[TBL] [Abstract][Full Text] [Related]
14. Angiogenic switch in multiple myeloma.
Giuliani N; Colla S; Rizzoli V
Hematology; 2004; 9(5-6):377-81. PubMed ID: 15763977
[TBL] [Abstract][Full Text] [Related]
15. Induction of angiogenesis by normal and malignant plasma cells.
Hose D; Moreaux J; Meissner T; Seckinger A; Goldschmidt H; Benner A; Mahtouk K; Hillengass J; Rème T; De Vos J; Hundemer M; Condomines M; Bertsch U; Rossi JF; Jauch A; Klein B; Möhler T
Blood; 2009 Jul; 114(1):128-43. PubMed ID: 19299335
[TBL] [Abstract][Full Text] [Related]
16. The ratio of VEGF/PEDF expression in bone marrow mesenchymal stem cells regulates neovascularization.
Fan W; Crawford R; Xiao Y
Differentiation; 2011 Mar; 81(3):181-91. PubMed ID: 21236558
[TBL] [Abstract][Full Text] [Related]
17. [Study on angiogenesis of multiple myeloma in vitro].
Chen WM; Wu Y; Zhu JZ; Soria J; Mirshahi M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):310-4. PubMed ID: 12513764
[TBL] [Abstract][Full Text] [Related]
18. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis and multiple myeloma.
Giuliani N; Storti P; Bolzoni M; Palma BD; Bonomini S
Cancer Microenviron; 2011 Dec; 4(3):325-37. PubMed ID: 21735169
[TBL] [Abstract][Full Text] [Related]
20. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
Frost P; Shi Y; Hoang B; Lichtenstein A
Oncogene; 2007 Apr; 26(16):2255-62. PubMed ID: 17016437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
